Table 2.
Multivariable Cox Regression Analysis of Factors Associated with Outcome in Patients with High-Risk Prostate Cancer
| Variable | Systemic Progression | Death from prostate cancer | Death from any cause | ||||||
|---|---|---|---|---|---|---|---|---|---|
| HR | 95% CI | P | HR | 95% CI | P | HR | 95% CI | P | |
| Age | 0.98 | 0.96, 1.00 | 0.02 | 0.99 | 0.97, 1.01 | 0.34 | 1.05 | 1.04, 1.06 | <0.0001 |
| Year of treatment | 0.96 | 0.93, 1.00 | 0.04 | 0.95 | 0.90, 1.00 | 0.03 | 0.97 | 0.94, 1.00 | 0.04 |
| Log2 PSA | 1.16 | 1.05, 1.28 | 0.002 | 1.17 | 1.03, 1.32 | 0.01 | 1.09 | 1.02, 1.17 | 0.008 |
| Biopsy Gleason score | 1.44 | 1.29, 1.62 | <0.0001 | 1.60 | 1.39, 1.84 | <0.0001 | 1.24 | 1.14, 1.34 | <0.0001 |
| 2002 AJCC tumor classification (cT2 vs cT1c) | 1.74 | 1.12, 2.69 | 0.01 | 1.97 | 1.09, 3.58 | 0.03 | 1.14 | 0.89, 1.45 | 0.30 |
| 2002 AJCC tumor classification (cT3/4 vs cT1c) | 2.42 | 1.54, 3.79 | 0.0001 | 2.55 | 1.39, 4.70 | 0.003 | 1.20 | 0.93, 1.56 | 0.17 |
| Treatment (EBRT vs RRP) | 1.53 | 1.05, 2.23 | 0.03 | 2.14 | 1.35, 3.39 | 0.001 | 2.04 | 1.62, 2.56 | <0.0001 |
| Treatment (EBRT/ADT vs RRP) | 0.78 | 0.51, 1.18 | 0.23 | 1.14 | 0.68, 1.91 | 0.61 | 1.60 | 1.25, 2.05 | 0.0002 |
HR indicates hazard ratio; CI, confidence interval; PSA, prostate-specific antigen; AJCC, American Joint Commission on Cancer; RRP, radical retropubic prostatectomy; EBRT, external-beam radiation therapy; ADT, androgen-deprivation therapy.